Gilead Sciences (GILD) 100.69 $GILD
UnitedHealth bulks up for prescription drug cost battle
By TOM MURPHY - AP - 12 mins ago
The nation's largest health insurer, UnitedHealth, will muscle up for its fight against rising prescription drug costs by spending more than $12 billion to buy pharmacy benefits manager Catamaran Corp.
JNJ: 101.55 (+1.21), ESRX: 85.40 (+3.02), CTRX: 59.83 (+11.51), GILD: 100.69 (-0.31), UNH: 121.00 (+2.99), CCT.TO: 75.88 (+15.04)
Gilead Sciences Inc. Faces An Uncertain Future After Patent Loss In India
Rami Alsamaraee - at Seeking Alpha - Mon Mar 30, 1:07PM CDT
GILD: 100.69 (-0.31)
Midday Glance: Biotechnology companies
AP - Mon Mar 30, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
Early Glance: Biotechnology companies
AP - Mon Mar 30, 9:56AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
Gilead Sciences (GILD) Crosses Pivot Point Support at $100.57
Comtex SmarTrend(R) - Mon Mar 30, 9:39AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bearishly opened below the pivot of $101.33 today and have reached the first support level of $100.57. Investors may be interested in a cross of the next downside pivot targets of $100.13 and $98.93.
GILD: 100.69 (-0.31)
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex
CBM: 35.59 (+0.66), GILD: 100.69 (-0.31), ACHN: 10.24 (+0.08), BMY: 65.76 (+0.50)
The Best Dividend-Paying Healthcare Stocks
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 29, 12:07PM CDT
Dividend investing has been shown to outperform investing in companies that offer no payouts, but that doesn't mean all dividend payers are created equal. In health care, for example, patent expiration can mean some dividend-paying stocks pose...
GILD: 100.69 (-0.31), AZN: 69.94 (-0.13), UNH: 121.00 (+2.99), BMY: 65.76 (+0.50)
3 Best Dividend Stocks for 2015
Selena Maranjian, The Motley Fool - Motley Fool - Sun Mar 29, 11:12AM CDT
We're still in the first quarter of 2015, and many investors are on the lookout for strong dividend-paying stocks. It's smart to seek dividends, as they can significantly enhance your total returns, delivering growth even when the overall market is...
NOV: 49.84 (+0.59), GILD: 100.69 (-0.31), AAPL: 126.37 (+3.12)
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 100.69 (-0.31), ACHN: 10.24 (+0.08), MRK: 58.34 (+0.59), IBB: 351.32 (+3.86), ABBV: 58.24 (+0.59)
The Biggest Red Flag for Biotech Investors
George Budwell, The Motley Fool - Motley Fool - Sat Mar 28, 9:03AM CDT
Source: Wikimedia Biotechnology can be an absolute minefield for investors due to its inherent complexity. The process of developing a medical product, navigating treacherous regulatory pathways, and subsequently convincing doctors to prescribe it...
GILD: 100.69 (-0.31)
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 123.89 (+9.48), BIIB: 431.62 (+1.75), ESRX: 85.40 (+3.02), GILD: 100.69 (-0.31), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 27, 6:59PM CDT
Cramer will look for any inkling of growth when industrial stocks report earnings next week.
GD: 137.51 (+2.47), BIIB: 431.62 (+1.75), F: 16.16 (+0.18), LMT: 204.89 (+2.66), SHAK: 49.62 (+0.62), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), RTN: 110.99 (+1.06), NOC: 162.68 (+2.20), GMCR: 113.96 (+0.76), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), JACK: 97.04 (+0.73), KMX: 69.22 (+2.53), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), REGN: 459.78 (+5.28), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), NXPI: 102.43 (+2.51), PLKI: 60.74 (+0.73), FRGI: 62.03 (+0.06), CELG: 120.02 (+1.34), MS: 36.31 (+0.48), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), GILD: 100.69 (-0.31), NDLS: 17.54 (-0.06), GM: 37.68 (+0.37), MCD: 97.88 (+0.92), DOW: 48.68 (+0.92), AVGO: 130.55 (+2.34), LLL: 126.69 (+1.46)
Hot Stocks Gilead, Alaska Air Work On New Bases
at Investor's Business Daily - Fri Mar 27, 5:19PM CDT
Many IBD 50 stocks are getting support at their 10-week moving averages as they continue to hold up well despite recent market turbulence. Biotech stock Gilead Sciences (GILD) is working on a 21-week consolidation with a possible buy point at 116.93....
NOAH: 23.21 (+0.05), SWI: 51.18 (+0.63), SNCR: 47.40 (+0.46), GILD: 100.69 (-0.31), FB: 83.19 (-0.11), ORLY: 219.38 (+3.96), ALK: 66.20 (+0.61)
Final Glance: Biotechnology companies
AP - Fri Mar 27, 5:10PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ABMD: 73.47 (+3.16), BIIB: 431.62 (+1.75), BMY: 65.76 (+0.50), GSK: 47.20 (+0.18), HUM: 181.18 (+3.66), MEIP: 1.75 (+0.01), DVA: 82.17 (+0.34), PFS: 18.69 (+0.28), GILD: 100.69 (-0.31), MRK: 58.34 (+0.59), CLLS: 35.20 (+0.20), HHS: 7.84 (+0.08), OHRP: 2.81 (+0.07), THRX: 16.60 (+0.14), REGN: 459.78 (+5.28)
Young Investors Should Hope for a Pullback Sooner Rather Than Later
at The Street - Fri Mar 27, 1:53PM CDT
The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.
AMZN: 374.59 (+4.03), ZIOP: 11.61 (+0.17), XBI: 224.37 (+4.96), IBB: 351.32 (+3.86), INXN: 28.06 (-0.87), TLT: 130.41 (-0.65), TBT: 42.07 (+0.39), LEN: 51.49 (+1.06), SPY: 208.25 (+2.51), QQQ: 106.73 (+1.21), XHB: 36.85 (+0.65), P: 16.39 (+0.07), GILD: 100.69 (-0.31), KITE: 59.98 (+0.20), PHM: 22.44 (+0.42), DIA: 179.39 (+2.58), ITB: 28.26 (+0.47), JUNO: 60.75 (+4.15), IWM: 124.77 (+1.67), KBH: 15.66 (+0.38), AAPL: 126.37 (+3.12), ZU: 13.37 (+0.44), BABA: 83.90 (-0.68)
Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 1:50PM CDT
Gilead's (GILD) announced that that the Japanese Ministry of Health, Labour and Welfare has approved its hepatitis C virus (HCV) drug Sovaldi.
CBM: 35.59 (+0.66), GILD: 100.69 (-0.31), ACHN: 10.24 (+0.08), BMY: 65.76 (+0.50)
A Buyback Or Biotech Bubble?
Leo Kolivakis - Seeking Alpha - Fri Mar 27, 1:37PM CDT
(click to enlarge) Steven Davidoff Solomon, professor of law at the University of California, Berkeley, wrote a comment for the New York Times reports, General Motors' Stock Buyback Follows a Worrying Trend : General Motors' announcement that...
BIIB: 431.62 (+1.75), GILD: 100.69 (-0.31), XBI: 224.37 (+4.96), IBB: 351.32 (+3.86), PKW: 49.69 (+0.67), CELG: 120.02 (+1.34)
Building A Better (Balanced) Dividend Growth Portfolio
Nicholas Ward - at Seeking Alpha - Thu Mar 26, 8:29PM CDT
WFM: 52.35 (+0.42), KMI: 42.07 (+0.80), KO: 40.51 (+0.43), GE: 25.12 (+0.26), HSY: 102.43 (+0.54), DLR: 66.76 (+1.03), POT: 32.40 (+0.37), WFC: 54.77 (+0.65), CB: 101.84 (+1.49), ORCL: 43.44 (+0.80), SJM: 117.13 (+1.12), T: 32.97 (+0.22), RDS.B: 63.99 (+0.40), PH: 119.31 (+1.16), GILD: 100.69 (-0.31), WPC: 67.90 (+0.42), QCOM: 68.88 (+1.85), DE: 88.61 (+1.15), MCD: 97.88 (+0.92), BP: 39.84 (+0.23), CVX: 106.90 (+2.62), GIS: 56.35 (+1.36), VZ: 49.12 (+0.56), AAPL: 126.37 (+3.12)
UnitedHealth bulks up for prescription drug cost battle
By TOM MURPHY - AP - 12 mins ago
The nation's largest health insurer, UnitedHealth, will muscle up for its fight against rising prescription drug costs by spending more than $12 billion to buy pharmacy benefits manager Catamaran Corp.
JNJ: 101.55 (+1.21), ESRX: 85.40 (+3.02), CTRX: 59.83 (+11.51), GILD: 100.69 (-0.31), UNH: 121.00 (+2.99), CCT.TO: 75.88 (+15.04)
Gilead Sciences Inc. Faces An Uncertain Future After Patent Loss In India
Rami Alsamaraee - at Seeking Alpha - Mon Mar 30, 1:07PM CDT
GILD: 100.69 (-0.31)
Midday Glance: Biotechnology companies
AP - Mon Mar 30, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
Early Glance: Biotechnology companies
AP - Mon Mar 30, 9:56AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
Gilead Sciences (GILD) Crosses Pivot Point Support at $100.57
Comtex SmarTrend(R) - Mon Mar 30, 9:39AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bearishly opened below the pivot of $101.33 today and have reached the first support level of $100.57. Investors may be interested in a cross of the next downside pivot targets of $100.13 and $98.93.
GILD: 100.69 (-0.31)
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex
CBM: 35.59 (+0.66), GILD: 100.69 (-0.31), ACHN: 10.24 (+0.08), BMY: 65.76 (+0.50)
The Best Dividend-Paying Healthcare Stocks
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 29, 12:07PM CDT
Dividend investing has been shown to outperform investing in companies that offer no payouts, but that doesn't mean all dividend payers are created equal. In health care, for example, patent expiration can mean some dividend-paying stocks pose...
GILD: 100.69 (-0.31), AZN: 69.94 (-0.13), UNH: 121.00 (+2.99), BMY: 65.76 (+0.50)
3 Best Dividend Stocks for 2015
Selena Maranjian, The Motley Fool - Motley Fool - Sun Mar 29, 11:12AM CDT
We're still in the first quarter of 2015, and many investors are on the lookout for strong dividend-paying stocks. It's smart to seek dividends, as they can significantly enhance your total returns, delivering growth even when the overall market is...
NOV: 49.84 (+0.59), GILD: 100.69 (-0.31), AAPL: 126.37 (+3.12)
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 100.69 (-0.31), ACHN: 10.24 (+0.08), MRK: 58.34 (+0.59), IBB: 351.32 (+3.86), ABBV: 58.24 (+0.59)
The Biggest Red Flag for Biotech Investors
George Budwell, The Motley Fool - Motley Fool - Sat Mar 28, 9:03AM CDT
Source: Wikimedia Biotechnology can be an absolute minefield for investors due to its inherent complexity. The process of developing a medical product, navigating treacherous regulatory pathways, and subsequently convincing doctors to prescribe it...
GILD: 100.69 (-0.31)
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 123.89 (+9.48), BIIB: 431.62 (+1.75), ESRX: 85.40 (+3.02), GILD: 100.69 (-0.31), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 27, 6:59PM CDT
Cramer will look for any inkling of growth when industrial stocks report earnings next week.
GD: 137.51 (+2.47), BIIB: 431.62 (+1.75), F: 16.16 (+0.18), LMT: 204.89 (+2.66), SHAK: 49.62 (+0.62), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), RTN: 110.99 (+1.06), NOC: 162.68 (+2.20), GMCR: 113.96 (+0.76), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), JACK: 97.04 (+0.73), KMX: 69.22 (+2.53), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), REGN: 459.78 (+5.28), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), NXPI: 102.43 (+2.51), PLKI: 60.74 (+0.73), FRGI: 62.03 (+0.06), CELG: 120.02 (+1.34), MS: 36.31 (+0.48), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), GILD: 100.69 (-0.31), NDLS: 17.54 (-0.06), GM: 37.68 (+0.37), MCD: 97.88 (+0.92), DOW: 48.68 (+0.92), AVGO: 130.55 (+2.34), LLL: 126.69 (+1.46)
Hot Stocks Gilead, Alaska Air Work On New Bases
at Investor's Business Daily - Fri Mar 27, 5:19PM CDT
Many IBD 50 stocks are getting support at their 10-week moving averages as they continue to hold up well despite recent market turbulence. Biotech stock Gilead Sciences (GILD) is working on a 21-week consolidation with a possible buy point at 116.93....
NOAH: 23.21 (+0.05), SWI: 51.18 (+0.63), SNCR: 47.40 (+0.46), GILD: 100.69 (-0.31), FB: 83.19 (-0.11), ORLY: 219.38 (+3.96), ALK: 66.20 (+0.61)
Final Glance: Biotechnology companies
AP - Fri Mar 27, 5:10PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ABMD: 73.47 (+3.16), BIIB: 431.62 (+1.75), BMY: 65.76 (+0.50), GSK: 47.20 (+0.18), HUM: 181.18 (+3.66), MEIP: 1.75 (+0.01), DVA: 82.17 (+0.34), PFS: 18.69 (+0.28), GILD: 100.69 (-0.31), MRK: 58.34 (+0.59), CLLS: 35.20 (+0.20), HHS: 7.84 (+0.08), OHRP: 2.81 (+0.07), THRX: 16.60 (+0.14), REGN: 459.78 (+5.28)
Young Investors Should Hope for a Pullback Sooner Rather Than Later
at The Street - Fri Mar 27, 1:53PM CDT
The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.
AMZN: 374.59 (+4.03), ZIOP: 11.61 (+0.17), XBI: 224.37 (+4.96), IBB: 351.32 (+3.86), INXN: 28.06 (-0.87), TLT: 130.41 (-0.65), TBT: 42.07 (+0.39), LEN: 51.49 (+1.06), SPY: 208.25 (+2.51), QQQ: 106.73 (+1.21), XHB: 36.85 (+0.65), P: 16.39 (+0.07), GILD: 100.69 (-0.31), KITE: 59.98 (+0.20), PHM: 22.44 (+0.42), DIA: 179.39 (+2.58), ITB: 28.26 (+0.47), JUNO: 60.75 (+4.15), IWM: 124.77 (+1.67), KBH: 15.66 (+0.38), AAPL: 126.37 (+3.12), ZU: 13.37 (+0.44), BABA: 83.90 (-0.68)
Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 1:50PM CDT
Gilead's (GILD) announced that that the Japanese Ministry of Health, Labour and Welfare has approved its hepatitis C virus (HCV) drug Sovaldi.
CBM: 35.59 (+0.66), GILD: 100.69 (-0.31), ACHN: 10.24 (+0.08), BMY: 65.76 (+0.50)
A Buyback Or Biotech Bubble?
Leo Kolivakis - Seeking Alpha - Fri Mar 27, 1:37PM CDT
(click to enlarge) Steven Davidoff Solomon, professor of law at the University of California, Berkeley, wrote a comment for the New York Times reports, General Motors' Stock Buyback Follows a Worrying Trend : General Motors' announcement that...
BIIB: 431.62 (+1.75), GILD: 100.69 (-0.31), XBI: 224.37 (+4.96), IBB: 351.32 (+3.86), PKW: 49.69 (+0.67), CELG: 120.02 (+1.34)
Building A Better (Balanced) Dividend Growth Portfolio
Nicholas Ward - at Seeking Alpha - Thu Mar 26, 8:29PM CDT
WFM: 52.35 (+0.42), KMI: 42.07 (+0.80), KO: 40.51 (+0.43), GE: 25.12 (+0.26), HSY: 102.43 (+0.54), DLR: 66.76 (+1.03), POT: 32.40 (+0.37), WFC: 54.77 (+0.65), CB: 101.84 (+1.49), ORCL: 43.44 (+0.80), SJM: 117.13 (+1.12), T: 32.97 (+0.22), RDS.B: 63.99 (+0.40), PH: 119.31 (+1.16), GILD: 100.69 (-0.31), WPC: 67.90 (+0.42), QCOM: 68.88 (+1.85), DE: 88.61 (+1.15), MCD: 97.88 (+0.92), BP: 39.84 (+0.23), CVX: 106.90 (+2.62), GIS: 56.35 (+1.36), VZ: 49.12 (+0.56), AAPL: 126.37 (+3.12)
